Replies to post #3681 on Biotech Values

[rkcrules2001]

Potential Pump Head Treatment

PARS will soon be releasing results of a Ph II trial on this...

From their last 10-Q:
"In March 2003, the Company initiated a double-blinded placebo controlled Phase II trial of dexanabinol as a preventive agent against the cognitive impairment (CI) that can follow coronary surgery involving cardiopulmonary bypass (CS-CPB) operations. In mid-July 2004, the Company completed enrollment of 202 CS-CPB patients in its Phase II clinical trial of dexanabinol. The clinical protocol calls for a final follow-up examination of each patient three months after enrollment. Allowing time for completion of patient records and preparation of the database, Pharmos expects to unblind the data and announce the study results during the fourth quarter of 2004."

[rstor1]

+++Now, the inside of the machine's tubing has been coated to reduce the body's inflammatory response. +++

Alexion is has a MAB aimed at reducing the inflammatory response to CABG (biowatch - this is a competitor to tp-10). They did a study on the MAB vs placebo and found no improvement in cognitive impairment. Does not sound like the inflammation in itself is responsible.

Anyone here think PARS has a shot at this indication?

Bob